Clinical data for patients 2 months of age and older
- Of the 17 pediatric patients 2 months to <2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises.1
- Of the 26 pediatric patients 6 to 17 years of age in two 12-month studies of RAVICTI, 5 patients (19%) reported a total of 5 hyperammonemic crises.1
- Of 51 adult patients in a 12-month study of RAVICTI, 7 patients (14%) reported a total of 10 hyperammonemic crises.1
aSix uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonemic crises in patients with urea cycle disorders (UCDs): 17 pediatric patients 2 months to <2 years of age, with 6 patients completing 12 months of treatment; 26 pediatric patients 6 to 17 years of age over a 12-month period; and 51 adults over a 12-month period.1
RAVICTI: Effective, 24/7 ammonia control with easy dosing1
- Easy-to-administer oral liquid that is nearly tasteless and odorless1,2
- Approved to treat UCD subtypes except NAGS deficiency1
- No pill or powder preparation1,2
- Easy for patients to make the switch from sodium phenylbutyrate (NaPBA) without any gap in treatment1
- Taken with meals via oral dosing syringe1
- With a simple calculation, dosage can be converted from NaPBA to RAVICTI1
RAVICTI is contraindicated in patients with known hypersensitivity to phenylbutyrate.1
Get information about RAVICTI dosing
How to calculate the appropriate starting dose for treatment-naïve patients, convert the dosage from NaPBA to RAVICTI, and optimize the RAVICTI dosage
Get everything you need to know about starting, switching, and refining treatment with RAVICTI.
Review efficacy data, safety information, mechanism of action, and dosing and administration.
References: 1. RAVICTI [package insert]. Lake Forest, IL: Horizon Pharma USA, Inc.; 2017. 2. Mosteller RD. N Engl J Med. 1987;317(17):1098. doi:10.1056/nejm198710223171717.